Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 11, 2005. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons. It details changes in share interests resulting from dividend reinvestments and employee share plan activities.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions and share prices associated with specific plans.
- Share Price (ADR): $48.22, $47.625, and $49.95 (varied by plan and transaction date).
- Share Price (Ordinary Share): £13.39 and £13.51.
- Dividend Date: July 7, 2005.
Material Changes
The filing reports increases in share interests for various directors and executives due to the reinvestment of dividends paid on July 7, 2005. Specific plans involved include the Executive Supplemental Savings Plan, the SmithKline Beecham Mid-Term Incentive Plan, the Performance Share Plan, and the ShareReward Plan. Additionally, the GSK Trust transferred 4,993 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity and does not contain forward-looking statements or risk assessments.
Important Facts for Investors to Verify
- Confirm the total number of shares acquired by key executives (e.g., Dr. J P Garnier, Mr. W Calhoun) across all listed plans to assess total insider accumulation.
- Verify the specific vesting conditions for the Performance Share Plan notional dividends mentioned in the filing.
- Check the current market price of GSK ADRs and Ordinary Shares to compare against the transaction prices of $47.625–$49.95 and £13.39–£13.51.
- Review the full terms of the SmithKline Beecham Employee Share Option Plan 1991 regarding the 4,993 shares transferred from the GSK Trust.